These innovative compounds represent a significant advancement in the management of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates promising efficacy in reducing blood glucose https://cyrustown071541.blogripley.com/39902998/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide